RegulationPriority Review (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea), Priority Review (Japan)

Structure/Sequence

Sequence Code 9474006L

Source: *****

Sequence Code 9474023H

Source: *****

Clinical Trials associated with Rozanolixizumab

NCT07465289

/ Not yet recruitingPhase 3

A Phase 3, Open-Label, Extension Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.

Start Date27 Jul 2026

Sponsor / Collaborator

UCB Biopharma SRL

NCT07570589

/ RecruitingNot ApplicableIIT

An Observational, Prospective, Multicenter, Open-label Study to Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)

Generalized Myasthenia Gravis (gMG) is a rare autoimmune disease (a disease in which the body attacks its own tissues) that causes muscle weakness and significant fatigue.
Current treatments (corticosteroids, plasma exchange, intravenous immunoglobulin infusions) improve symptoms in many patients. However, many continue to suffer from fatigue and fatigability that are not well measured by standard tools. Moreover, these treatments can cause significant long-term side effects, reducing quality of life.
New treatments such as Rozanolixizumab (ROZ) are now available. They act rapidly and are well tolerated, allowing better symptom control while reducing the risks associated with conventional treatments.
To properly evaluate these new treatments, it is essential to understand patients' perspectives on their effectiveness. The scales used by physicians do not always capture all the symptoms experienced by patients, particularly fatigability. This is why a new tool has been developed: the MG symptoms PRO. This questionnaire allows patients to assess their own symptoms (fatigue, weakness of the eyes, mouth, breathing, muscle fatigability) in detail.
This research aims to better understand the effectiveness of treatments from the patients' perspective in order to improve their care.
The goal of the study is to evaluate the impact of Rozanolixizumab administration in real-world practice through the MG symptoms PRO questionnaire. This is an observational study, meaning that the medication is prescribed by the physician according to current regulations, and the study simply collects routine medical data during your follow-up, over a period of approximately 9 months.

Start Date15 Jun 2026

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nice

NCT07463521

/ RecruitingPhase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.

Start Date27 May 2026

Sponsor / Collaborator

UCB Biopharma SRL

100 Clinical Results associated with Rozanolixizumab

100 Translational Medicine associated with Rozanolixizumab

100 Patents (Medical) associated with Rozanolixizumab

Literatures (Medical) associated with Rozanolixizumab

01 Jul 2026·Neurohospitalist

Aseptic Meningitis Following Rozanolixizumab in a Patient With Refractory Anti-MuSK Positive Myasthenia Gravis: A Case Report

Article

Author: Maqsood, Hamza ; Fleming, James

Rozanolixizumab is a neonatal Fc receptor (FcRn) blocker recently approved for treating generalized myasthenia gravis (gMG), particularly in patients who are anti-AChR or anti-MuSK antibody positive. Although clinical trials have demonstrated a favorable safety profile, rare adverse neurological effects remain underreported. A 36-year-old woman with refractory anti-MuSK-positive generalized myasthenia gravis received an infusion of rozanolixizumab after failing to respond to corticosteroids and azathioprine. 5 days post-infusion, she presented with an acute-onset headache, nausea, vomiting, photophobia, phonophobia, and neck stiffness. Cerebrospinal fluid (CSF) analysis revealed a white blood cell count of 150 cells/μL with 90% neutrophils, normal protein, and glucose levels. The infectious meningitis and encephalitis panel was negative. She was managed supportively, and her symptoms resolved over the following week without antimicrobial therapy. This case suggests a possible link between Rozanolixizumab and aseptic meningitis. Clinicians should be aware of this potential adverse effect and consider drug-induced etiologies in similar clinical scenarios. Early recognition may prevent unnecessary treatment and hospitalizations.

01 May 2026·ADVANCES IN THERAPY

Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis

Article

Author: Hashim, Mahmoud ; Singh, Sumeet ; Ramchandren, Sindhu ; Keng, Mi Jun ; Gandhi, Kavita ; Slowik, Rafal ; Gilhus, Nils Erik ; Khoury, Antoine C El ; Hutton, Brian ; Van Sanden, Suzy ; Jacob, Saiju ; Drudge, Christopher

INTRODUCTION:

Nipocalimab, efgartigimod, and rozanolixizumab (the last two cyclically dosed) are approved neonatal Fc receptor (FcRn) blockers for treating generalized myasthenia gravis (gMG). No trials have directly compared these therapies; hence, indirect treatment comparisons (ITCs) were conducted to evaluate their relative efficacy.

METHODS:

Matching-adjusted indirect comparisons (MAICs) and Bucher ITCs were used to compare nipocalimab vs. efgartigimod and rozanolixizumab for changes from baseline (CFB) in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score observed in their phase 3 registration trials. Bucher ITCs used the relative treatment effect vs. placebo. As there was considerable cross-trial heterogeneity, including uncertainty in using the placebo arm as a common comparator, active treatment arms were used in unanchored MAICs. MG-ADL CFB was compared between trials (1) at multiple timepoints to evaluate onset of action and disease control over time, and (2) using area under the curve (AUC) as a measure of cumulative effect normalized per week of follow-up.

RESULTS:

In both Bucher ITCs and MAICs, nipocalimab had a comparable MG-ADL CFB at week 1 vs. the other FcRn blockers. In MAICs, MG-ADL CFB was significantly greater with nipocalimab vs. efgartigimod at week 8 sustained up to 24 weeks (p < 0.05), and vs. rozanolixizumab at week 10 sustained up to 14 weeks (p < 0.05); results numerically favored nipocalimab in corresponding Bucher ITCs. Using normalized AUC, MG-ADL CFB with nipocalimab was significantly greater in MAICs (p < 0.05) and numerically greater in Bucher ITCs vs. the other FcRn blockers.

CONCLUSIONS:

Sustained disease control is an important consideration in managing chronic diseases with fluctuating symptoms such as gMG. Study results showed that nipocalimab provided a comparable onset of action and consistent and sustained disease control that was numerically or statistically significantly greater (depending on ITC method) when compared with the symptom-based cyclic FcRn blockers efgartigimod and rozanolixizumab.

03 Apr 2026·Immunological Medicine

Rozanolixizumab as rescue therapy in triple-seronegative refractory generalized myasthenia gravis

Article

Author: Yamakawa, Kentaro ; Tamaki, Shunsuke ; Inoue, Mari ; Takenobu, Yohei ; Hatano, Karen ; Miyahara, Junichi ; Higuchi, Osamu ; Nomura, Noriko ; Kikuchi, Takayuki ; Yukawa, Kayoko ; Ishikawa, Daiki ; Inoue, Manabu

Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction, most commonly associated with anti-acetylcholine receptor antibodies, less frequently with muscle-specific kinase antibodies, and occasionally with low-density lipoprotein receptor-related protein 4 antibodies. However, a subset of patients with MG tests negative for all of these three antibodies - termed triple-seronegative MG - posing significant diagnostic and therapeutic challenges. Fast-acting therapies, such as intravenous methylprednisolone (IVMP), intravenous immunoglobulin (IVIG) and plasma exchange (PLEX), are typically recommended during disease exacerbation. However, some patients are refractory to these interventions. For refractory patients with triple-seronegative MG, the efficacy of a recent monoclonal antibody therapy as rescue therapy remains uncertain. We report a case of triple-seronegative MG refractory to repeated IVIG, IVMP and PLEX, in which clinical improvement was achieved following treatment with rozanolixizumab. This case, with long-term follow-up, suggests the potential utility of rozanolixizumab as rescue therapy in a patient subgroup which is typically excluded from randomized controlled trials. Larger studies specifically including patients with triple-seronegative MG are warranted.

News (Medical) associated with Rozanolixizumab

12 Jun 2026

·www.prnewswire.com

Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced the appointment of Dr. Dhavalkumar Patel as Scientific Advisor. Dr. Patel brings an outstanding track record of therapeutic innovation spanning over two decades in industry and academia. He is currently Executive Vice President and Chief Scientific Officer of Sana Biotechnology. Prior to joining Sana Biotechnology in 2024, Dr. Patel served as Executive Vice President and Chief Scientific Officer of UCB, where he and his teams contributed to the registration of bimekizumab (Bimzelx®), rozanolixizumab (Rystiggo®) and zilucoplan (Zilbrysq®). Prior to UCB, he spent 10 years at Novartis, most recently as the Head of Research of the Novartis Institutes for BioMedical Research (NIBR) Europe. During his tenure, he led research in the autoimmune, transplantation, and inflammation disease areas, contributing to the registration of secukinumab (Cosentyx®), fingolimod (Gilenya®), siponimod (Mayzent®), canakinumab (Ilaris®), everolimus (Zortress®/Certican®, Afinitor®), leniolisib (Joenja®), and iptacopan (Fabhalta®) in multiple indications. He was also an Entrepreneur in Residence at the Novartis Venture Fund. Dr. Patel served as a member of the Board of Directors of Inflazome prior to its acquisition by Roche in 2020. He currently serves on the Boards of Directors for Priothera, Quell Therapeutics, and RE-AIM Therapeutics, and serves as Chair of the Board of Directors for Mimetas BV. Prior to joining industry in 2006, Dr. Patel was an Eminent Professor of Medicine, Chief of Rheumatology, Allergy and Clinical Immunology, and Director of the Thurston Arthritis Research Center at the University of North Carolina in Chapel Hill. He also spent nine years at the Duke University School of Medicine, culminating in his position as the Chief of the Division of Allergy and Immunology. Dr. Patel received his B.S., M.D., and Ph.D. in Microbiology and Immunology from Duke University, and is board certified in internal medicine, rheumatology, and allergy & immunology. "We are thrilled to welcome Dr. Patel to our Scientific Advisory Board," said Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. "His outstanding combination of deep immunological science, proven drug development success, and board-level strategic insight will be a tremendous asset to us. We look forward to his guidance as we continue to build a leading immunology pipeline." "I am honored to join Harbour BioMed as a Scientific Advisor," said Dr. Dhavalkumar Patel. "Harbour BioMed has built a compelling portfolio of novel antibody candidates targeting key immune pathways, and I believe the company is well-positioned to make meaningful progress in areas of high unmet medical need. I look forward to working closely with the team to help advance these programs from discovery through development and ultimately to patients." About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions. Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUSTM) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIxTM AI platform, accelerating the development of innovative therapies. By integrating Harbour Mice®, HBICE®, HCAb PLUSTM, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit . SOURCE Harbour BioMed 21% more press release views with Request a Demo

Executive Change

11 Jun 2026

·www.fiercepharma.com

J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win

Johnson & Johnson has revealed data from a trial which could pave the way for a label expansion which would make Imaavy the first approved treatment for warm autoimmune hemolytic anemia. Last year, Johnson & Johnson arrived late to the party with Imaavy as the third FcRn blocker approved since 2021 to treat patients with generalized myasthenia gravis (gMG). But J&J has hopes for the monoclonal antibody in several other indications, including one rare disease in which it appears to be setting the pace—warm autoimmune hemolytic anemia (wAIHA). On Thursday, the company unveiled data from a pivotal phase 2/3 trial which could pave the way for a label expansion for Imaavy.In the Energy study, Imaavy worked quickly and elicited a statistically significant durable red blood-cell count response in patients with wAIHA, a life-threatening disorder which has no approved therapies. There is an urgent unmet need in the indication, where patients to rely on corticosteroids and immunosuppressive therapies which do not address the underlying cause of the disorder, according to J&J.The trial, which included 115 participants who were randomized 1:1:1 to receive two different doses of Imaavy or placebo, showed that three times as many patients who were infused with a 30 mg/kg dose of Imaavy achieved durable hemoglobin (Hgb) levels versus those on placebo after 24 weeks. The primary endpoint of the study was defined as an increase from baseline in Hgb of at least 2 g/dL and an Hgb concentration of at least 10 g/dL for at least 28 days without the need for rescue therapy or alterations in background treatment. Nearly two-thirds of treated patients achieved both of these targets by Week 24, J&J said.“Achieving hemoglobin improvements this quickly and at this scale is important in clinical practice, as it could help improve the debilitating fatigue that people living with warm autoimmune hemolytic anemia experience,” Bruno Fattizzo, M.D., of the Department of Oncology and Hematology-Oncology at the University of Milan, Italy, said in a release.Changes in patient-reported fatigue were seen as early as Week 2 in the trail and sustained throughout the treatment period, which was a key secondary endpoint. Another secondary objective, reductions in steroid use, also was achieved, J&J said. Imaavy also demonstrated a safety profile consistent with its use in gMG.J&J has already submitted for approval in the indication at the 30 mg/kg dose, gaining an FDA priority review designation in April, becoming the first to do so in the indication. The key to Imaavy’s effectiveness in the indication is its “immunoselective approach,” according to J&J’s Disease Area Leader for Autotibody and Rheumatology, Leonard Dragone, M.D., Ph.D.Imaavy “targets the underlying autoantibodies driving disease while preserving key immune functions, which is important for people living with this disease who frequently suffer with comorbid conditions,” he said in the release.J&J acquired Imaavy in its $6.5 billion buyout of Momenta Pharmaceuticals in 2020. The company has tabbed the treatment with peak sales potential of $5 billion or more and is investigating its use in a host of autoimmune disorders including Sjogren’s disease, hemolytic disease of the fetus and newborn and fetal neonatal alloimmune thrombocytopenia. Each of the programs are in phase 3 testing and have received FDA fast-track designation. J&J also has advanced Imaavy to phase 3 in chronic inflammatory demyelinating polyneuropathy and to phase 2 in systemic lupus erythematosus and idiopathic inflammatory myopathy.Last year, after coming up short in a phase 2a trial, the company bailed on its attempt to advance Imaavy as a combo agent in rheumatoid arthritis.Beating J&J to the finish line with FcRn blockers to treat gMG were argenx, which gained its approval for Vyvgart in 2021 and reported its sales at $4.2 billion in 2025, and UCB, which scored an FDA nod for Rystiggo in 2023 and reported its 2025 sales at 332 million euros ($375 million). J&J has yet to divulge sales of Imaavy, which it launched in April of last year, with the broadest label in the indication.

Clinical ResultPhase 3Drug ApprovalPhase 2Priority Review

11 Jun 2026

·allsci.com

TG Therapeutics aiming to expand Briumvi to myasthenia gravis after positive early data

TG Therapeutics (Nasdaq: TGTX) reported Phase I data showing that subcutaneous ublituximab (Briumvi), its glycoengineered anti-CD20 B-cell depleting antibody, produced clinically meaningful improvements in myasthenia gravis (MG) patients. The firm indicated that a Phase II trial will be initiated testing a sequential treatment strategy pairing an FcRn inhibitor for rapid symptom control followed by ublituximab for sustained B-cell depletion. TG is intent on expanding Briumvi beyond its approved multiple sclerosis indication into a generalized MG market that has grown substantially more competitive. The Phase II design — using argenx’s Vyvgart (efgartigimod alfa) as an induction agent before randomizing to ublituximab or placebo — is an unusual attempt to combine two mechanistically distinct drug classes in a sequential regimen. Trial data The Phase I cohort enrolled 11 adults with acetylcholine receptor antibody-positive MG (mean age 74; mean baseline MG-ADL 8.24), receiving subcutaneous ublituximab at exposures demonstrated to be at least equivalent to the approved intravenous regimen. At Week 24, 82% of patients achieved the minimal clinically important difference in MG-ADL (defined as a ≥2-point decrease), with a median time to MCID of 30 days. Mean MG-ADL improvement was 4.6 points. The safety profile was described as generally consistent with the established intravenous Briumvi profile in MS. These are small-sample, uncontrolled data and should be interpreted with caution; the absence of a comparator arm precludes conclusions about relative efficacy. The Phase II trial, now enrolling approximately 120 patients, uses a single induction cycle of efgartigimod (four weekly infusions), then randomizes MG-ADL responders 1:1 to intravenous ublituximab or placebo for 24 weeks. The primary endpoint is time to clinical worsening, defined as a ≥2-point MG-ADL increase or myasthenic crisis requiring hospitalization. A 72-week open-label extension follows. Competitive context The MG treatment landscape is crowded with approved FcRn inhibitors — argenx’s Vyvgart, Johnson & Johnson’s Imaavy (nipocalimab), and UCB’s Rystiggo (rozanolixizumab) — as well as complement inhibitors and, in late-stage development, BCMA-directed CAR-T therapies from Cartesian Therapeutics (Nasdaq: RNAC) and Kyverna Therapeutics (Nasdaq: KYTX). Ublituximab’s proposed differentiation rests on durable B-cell depletion as a maintenance strategy following FcRn-mediated rapid IgG reduction, a hypothesis the Phase II is designed to test. Cross-trial comparisons are limited by differences in patient populations, trial design, and endpoints. The Phase II is described as potentially registration-directed, though TG has cautioned that a successful result would not automatically qualify as a registrational study. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 2Phase 1Clinical ResultImmunotherapyCell Therapy

100 Deals associated with Rozanolixizumab

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14919

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thrombocytopenia	Canada	UCB SA	01 Mar 2025
Myasthenia Gravis	United States	UCB, Inc.	26 Jun 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myasthenia Gravis, Ocular	Phase 3	United States	UCB Biopharma SRL	27 May 2026
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	United States	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Japan	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Australia	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Belgium	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Brazil	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Czechia	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	France	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Germany	UCB Biopharma SRL	02 Feb 2022
Myelin oligodendrocyte glycoprotein antibody-associated disease	Phase 3	Greece	UCB Biopharma SRL	02 Feb 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06720714 (CTgov)	Phase 1	-	15	Rozanolixizumab	dpodypevgw(qqvnafgmfb) = xsgebrwixp uvlweipdbd (bjczmyttzq, NA) View more	-	04 Jun 2026
MDA2026	Not Applicable	Myasthenia Gravis anti-acetylcholine receptor antibody-positive \| anti-muscle-specific tyrosine kinase antibody-positive	26	Rozanolixizumab + Rozanolixizumab (gMG)	yjrvusdmpg(toybdqofra) = aqejaitamo qfkurskcot (fposmyaytl ) View more	Positive	08 Mar 2026
NCT03971422 (MycarinG, Pubmed \| J Neurol)	Phase 3	Myasthenia Gravis	200	Rozanolixizumab 7 mg/kg	tdsjxfeavk(ajolhkumce) = mmjtabtyeg awivvuhjkl (hhrmbzecgg ) View more	Positive	01 Dec 2025
				Rozanolixizumab 10 mg/kg	tdsjxfeavk(ajolhkumce) = qozmhmaaoq awivvuhjkl (hhrmbzecgg ) View more
NCT05681715 (MG0020, Pubmed \| J Neurol)	Phase 3	Myasthenia Gravis	55	Rozanolixizumab	qwdjwuygof(ddvdspbdkt) = crcgdgmqjg ybtcaxonrc (zujjmwaetd ) View more	Positive	01 Oct 2025
NCT03971422 (MycarinG, Pubmed \| Eur J Neurol)	Phase 3	Myasthenia Gravis	164	Rozanolixizumab 7 mg/kg	rslrecwoll(weoiwjuwdc) = utppbcaaof hpiptewebr (iiedvpwfsj ) View more	Positive	01 Aug 2025
				Rozanolixizumab 10 mg/kg	rslrecwoll(weoiwjuwdc) = cithrpbbyr hpiptewebr (iiedvpwfsj ) View more
NCT04875975 (CTgov)	Phase 2	Autoimmune Encephalitis	12	Placebo	qtbemfvkkz = urmixwfpnm tkxeyauqog (lsocelvfip, edcccoalhq - qdlkpgjuce) View more	-	31 May 2025
NCT05681715 (MG0020, CTgov)	Phase 3	Myasthenia Gravis	62	RLZ SRD (Period 1: RLZ SRD)	iomqarwhxj = untnjxmmum fzgqtiswsp (mfazphvdiu, rfzqqwbggk - cwwxzdqhix) View more	-	07 May 2025
				RLZ (Period 1: RLZ MP)	iomqarwhxj = frwtlgjsxn fzgqtiswsp (mfazphvdiu, voikxibthg - kqlpvalysl) View more
NCT04650854 (CTgov)	Phase 3	Myasthenia Gravis	165	Rozanolixizumab (Rozanolixizumab ~7 mg/kg)	lztovfmjwu = jjgadhyfhu nsbpsrybcq (dditysvuui, nrhjiyhzbs - xhmfwktgmi) View more	-	18 Apr 2025
				Rozanolixizumab (Rozanolixizumab ~10 mg/kg)	lztovfmjwu = ahaormfvnr nsbpsrybcq (dditysvuui, czlmkfrokj - udkcmchotp) View more
NCT04124965 \| NCT04650854 (MG0004, Pubmed \| J Neurol)	Phase 3	Myasthenia Gravis acetylcholine receptor \| muscle-specific tyrosine kinase autoantibody-positive	70	Rozanolixizumab 7mg/kg	efctaxzoxt(zvijyqikwd) = 11/70 [15.7%] vykkcieidu (dpkgrfqdpo ) View more	Positive	01 Apr 2025
				Rozanolixizumab 10mg/kg
NCT04124965 (MG0004, MDA2025)	Phase 3	Myasthenia Gravis	70	Rozanolixizumab 7mg/kg	hwwvhvhlqf(yeyssolwrg) = cbonpijevv smwbbudqet (hkndfqpdup ) View more	Positive	16 Mar 2025
				Rozanolixizumab 10mg/kg	hwwvhvhlqf(yeyssolwrg) = fqqenwicuy smwbbudqet (hkndfqpdup ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis